Investigating Optimal Autologous Cellular Platforms for Prenatal or Perinatal Factor VIII Delivery to Treat Hemophilia A

Investigating Optimal Autologous Cellular Platforms for Prenatal or Perinatal Factor VIII Delivery to Treat Hemophilia A

Patients with the severe form of hemophilia A (HA) present with a severe phenotype, and can suffer from life-threatening, spontaneous hemorrhaging. While prophylactic FVIII infusions have revolutionized the clinical management of HA, this treatment is short-lived, expensive, and it is not available...

Full description

Bibliographic Details
Main Authors: Christopher Stem, Christopher Rodman, Ritu M. Ramamurthy, Sunil George, Diane Meares, Andrew Farland, Anthony Atala, Christopher B. Doering, H. Trent Spencer, Christopher D. Porada, Graça Almeida-Porada
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
gene therapy
hemophilia A
FVIII
endothelial progenitor cell
mesenchymal stromal (stem) cell therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2021.678117/full

Internet

https://www.frontiersin.org/articles/10.3389/fcell.2021.678117/full

Similar Items